Primary Breast Cancer Clinical Trial
Official title:
Breast Cancer Proteomics and Molecular Heterogeneity
Primary objective: The primary objective is to define the proteomic and molecular characteristics of primary and recurrent/ metastatic breast tumours with special focus on the expression of S100 protein and the estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2) genes Secondary objective: - To expand our understanding of the complex molecular pathways dictating the progression of breast cancer and their response to different treatment regimes. - To relate proteomic findings to survival data - To identify potential serum markers of breast cancer progression
This is a translational study. Patient will undergo standard treatment and tissue and blood samples will be taken at various time points: Tissue: Fresh frozen (FF) and Formalin fixed paraffin embedded tissue (FFPE) will be collected at time of surgery/biopsy of a primary or a recurrent/metastatic tumour tissue. Blood: Two types of study bloods (non-heparinised and Ethylenediaminetetraacetic acid (EDTA)) will be taken pre-neoadjuvant treatment (if applicable), pre- and post-operatively of primary and recurrent/ metastatic breast cancer (if recurrent/metastatic diagnosis and no biopsy/surgery required then study bloods will be taken prior to starting treatment). Additional blood samples will be taken annually at follow-up visits for 5 years from primary cases and for up to 2 years from recurrent/metastatic cases. Non-heparinised blood will be processed to serum. Clinical data will be collected at all times of biological sampling. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05923177 -
Molecular Imaging of HER2 Expression in Breast Cancer Using [123I] I-(HE)3-G3
|
Phase 1 | |
| Completed |
NCT01033162 -
Effectiveness of the CHESS eHealth Cancer Support Intervention in Population-based Care
|
N/A | |
| Recruiting |
NCT03270007 -
Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy
|
Phase 4 | |
| Completed |
NCT00527449 -
Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel
|
Phase 2 | |
| Completed |
NCT04468113 -
Clip Marker Placement in Primary Lesions of Breast Cancer Patients Receiving Neoadjuvant Therapy
|
||
| Recruiting |
NCT03711877 -
Comparative Study of Scalp Cooling System and Chemical Cold Cap (COHAIR Study)
|
Phase 3 | |
| Active, not recruiting |
NCT01019616 -
Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy
|
Phase 3 | |
| Completed |
NCT01314833 -
Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy
|
Phase 3 | |
| Completed |
NCT04127019 -
Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)
|
Phase 3 | |
| Terminated |
NCT00172068 -
Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow
|
Phase 2 | |
| Completed |
NCT01049425 -
Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer
|
Phase 3 | |
| Completed |
NCT01779479 -
Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE)
|
Phase 2 | |
| Completed |
NCT04277338 -
Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3
|
Phase 1 | |
| Recruiting |
NCT05445050 -
mULM to Support Breast Cancer Diagnosis and Therapy
|
N/A | |
| Completed |
NCT00793377 -
Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer
|
Phase 3 |